Development of a Predictive Model for Serious Adverse Drug Reaction in Psychiatric Patients Leading to the Use of Benztropine Injection by Using Data Mining Techniques

Main Article Content

Porntip Theraratchilert
Winyoo Chanakul
Janjao Mongkolnavin
Thanompong Sathienluckana
Siriwat Suwattanapreeda
Pornyupa Tiangphattanawong
Anusara Kraunual

Abstract

Objective: To develop a predictive model for an occurrence of serious adverse drug reactions, especially acute dystonia, leading to an administration of benztropine injection in psychiatric patients. Methods: Data of patients diagnosed with ICD10 F00.00 - F99.99, aging between 15 - 80 years old were gathered from Somdet Chaopraya institute of psychiatry’s database from January 2016 to December 2021. Subsequently, the collected data were then processed by a data selection algorithm with a predetermined set of variables to analyze the association with serious adverse drug reaction leading to an administration of benztropine injection.  Data were then cleaned, and used to generate a predictive model by a decision tree method via RapidMiner Studio program. The program’s parameters were later adjusted for maximum precision. Results: This study gathered data of 41,713 patients with 5.47% of a serious adverse drug reaction leading to an administration of benztropine injection. A total of 164 variables were established with 16 being significant for generating the decision tree. The important first-class variable was an increase in antipsychotic drug dosage within 7 days which accounted for 91.39% of the serious adverse drug reaction. The other significant variables in the predictive model were the receiving of short-acting haloperidol injection or antipsychotic medication with a daily dosage equal to 5 mg/day of risperidone (sum DDD>5) with no concomitant anticholinergic drug. Development of the predictive model by a decision tree method from this study had shown to predict an occurrence of a serious adverse drug reaction with an accuracy of 84.32% and recall of 85.31%. Conclusion: Acute dystonia is a serious drug adverse reaction of antipsychotic medications with appropriate monitoring needed, particularly in patients with high-risk, i.e., those with the increased dosage of antipsychotic drugs within 7 days.

Article Details

Section
Research Articles

References

Crismon M, Kattura RS, Buckley PF. Schizophrenia. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. editors. Pharmacotherapy: a pathophy siologic approach. 10th ed. New York, NY: McGraw Hill; 2017.

Mazurek MF, Rosebush PI. Acute drug-induced dystonia. In: Factor S, Lang A, Weiner W, editors. Drug induced movement disorders. 2nd ed. Boston, MA: Blackwell Publishing; 2005. p.72-102.

Annamalai A. Medical management of psychotropic side effects. New York, NY: Springer; 2017. p.235-244.

Blanchet PJ. Antipsychotic drug-induced movement disorders. Can J Neurol Sci. 2003; 30: S101-7.

Campbell D. The management of acute dystonic reactions. Aust Prescr. 2001; 24: 19-20.

Mathews M, Gratz S, Adetunji B, George V, Mathews M, Basil B. Antipsychotic-induced movement disor- ders: evaluation and treatment. Psychiatry(Edgmont) 2005; 2: 36-41.

Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophre- nia: factors influencing adherence and consequen- ces of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013; 3: 200-18.

Phan SV. Medication adherence in patients with schizophrenia. Int J Psychiatry Med. 2016; 51: 211-19.

Ostroumova TM, Tolmacheva VA, Ostroumova OD, Parfenov VA. Drug-induced dystonia. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(5):4-8.

Suzuki T, Matsuzaka H. Drug-induced Pisa syn drome (pleurothotonus): epidemiology and manage- ment. CNS Drugs. 2002; 16: 165-74.

Addonizio G, Alexopoulos GS. Drug-induced dysto nia in young and elderly patients. Am J Psychiatry. 1988; 145: 869-71.

Tarsy D. Movement disorders with neuroleptic drug treatment. Psychiatr Clin North Am. 1984; 7: 453-71.

van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ. 1999; 319: 623-26.

Wirshing WC. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry. 2001; 62 Suppl 21: 15-8.

Defazio G, Berardelli A, Abbruzzese G, Coviello V, Carella F, De Berardinis MT, et al. Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study group. J Neurol Neurosurg Psychia- try. 1999; 67: 613-9.

Park HW, Kwak JR, Lee JS. Clinical characteristics of acute drug-induced dystonia in pediatric patients. Clin Exp Emerg Med. 2017; 4: 133-7.

Loonen AJ, Ivanova SA. Neurobiological mecha- nisms associated with antipsychotic drug-induced dystonia. J Psychopharmacol. 2021; 35: 3-14.

Spina E, Sturiale V, Valvo S, et al. Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. Int Clin Psychopharmacol. 1993; 8: 21-4.

Satterthwaite TD, Wolf DH, Rosenheck RA, Gur RE, Caroff SN. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsy chotics for the treatment of agitation. J Clin Psychia try. 2008; 69: 1869-79.

Taylor D, Young A, Barnes TE. The Maudsley prescribing guidelines in psychiatry. New York. Wiley-Blackwell; 2018.

Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L. Suggested minimal effective dose of risperi done based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry. 1999; 156: 869-75.

Charoenchokthavee W, Panomvana D, Sriuranpong V, Areepium N. Prevalence of CYP2D6*2, CYP2D6 *4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment. Breast Cancer (Dove Med Press). 2016; 8: 149-55.

Hongkaew Y, Gaedigk A, Wilffert B, et al. Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone. Sci Rep. 2021; 11: 4158.

Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000; 157: 514-20.